View More View Less
  • 1 Szent Lázár Megyei Kórház, Salgótarján, Füleki út 54–56., 3100
  • 2 Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest
Open access

Absztrakt:

Mivel a vastagbéldaganatok terápiás lehetőségei limitáltak, az egyes kezelések újraindítása (rechallenge) a terápiás stratégia részévé vált. Ezt példázza esetünk is. 65 éves nőbetegnél sürgősséggel resectio történt sztenotizáló sigmadaganat miatt. Sebészileg inkurábilis multiplex májáttétek igazolódtak. Szövettan: adenocarcinoma (grade II, pT3pN1cM1). 13 ciklus bevacizumab (BEV) + FOLFOX, majd 2 ciklus BEV + kapecitabin és 11 ciklus BEV + 5FU/LV kezelést kapott. 2. vonalbeli terápiaként 28 ciklus cetuximab (CET) + FOLFIRI kezelésben részesült. A 3. vonalban – tekintettel a májra lokalizálódó betegségre és a páciens preferenciája alapján – két ciklus transarterialis chemoembolisatiót kapott (doxorubicin + lipiodol). A 4. vonalban 4 ciklus trifluridin/tipiracil kezelést kapott. Az 5. vonalban 13 ciklus BEV + FOLFIRI (rechallenge) kezelésben részesült, mely 6,5 hónappal hosszabbította meg az élettartamát. Orv Hetil. 2018; 159(31): 1284–1290.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016; 27: 1386–1422.

  • 2

    Cervantes A, Arnold D, Peeters M, et al. Redefining later-line therapy in metastatic colorectal cancer. EMJ 2017; 2: 31–37.

  • 3

    Bano N, Najam R, Quazi F, et al. Clinical features of oxaliplatin induced hypersensitivity reactions and therapeutic approaches. Asian Pac J Cancer Prev. 2016; 17: 1637–1641.

  • 4

    Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007; 12: 601–609.

  • 5

    Goldberg RM, Rothenberg ML, Van Cutsem E, et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007; 12: 38–50.

  • 6

    de Gramont A, Buyse M, Abrahantes JC, et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol. 2007; 25: 3224–3229.

  • 7

    Yeoh C, Chau I, Cunningham D, et al. Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials. Clin Colorectal Cancer 2003; 3: 102–107.

  • 8

    Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012; 23: 2479–2516.

  • 9

    Baldus SE, Schaefer KL, Engers E, et al. Prevalence and heterogeneity of KRAS, BRAF and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res. 2010; 16: 790–799.

  • 10

    Sagaert X, Vanstapel A, Verbeek S. Tumor heterogeneity in colorectal cancer: what do we know so far? Pathobiology 2018; 85: 72–84.

  • 11

    Ma SC, Zhao Y, Zhang T, et al. Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis. Onco Targets Ther. 2015; 8: 641–648.

  • 12

    Di Salvatore M, Orlandi A, Paolillo C, et al. ERCC1 biomarker in colorectal cancer: to induce or not to induce? This is the matter! Oncomedicine 2016; 1: 25–27.

  • 13

    Serban A, Hajdu KA, Banciu TI, al. The choice of irinotecan or oxaliplatin-based chemotherapy in metastatic colo-rectal cancer as first line treatment: Impact on survival (ERCC1 and TOPO1 adjusted analysis). Ann Oncol. 2017; 28 (Suppl 3): iii13–iii136.

  • 14

    Moutinho C, Martinez-Cardús A, Santos C, et al. Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer. Natl Cancer Inst. 2014; 106: djt322.

  • 15

    Martinez-Balibrea E, Martínez-Cardús A, Ginés A, et al. Tumor-related molecular mechanisms of oxaliplatin resistance. Mol Cancer Ther. 2015; 14: 1767–1776.

  • 16

    Sugimoto Y, Tsukahara S, Oh-hara T, et al. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res. 1990; 50: 6925–6930.

  • 17

    Cunningham JM, Prins P, Conkright B, et al. Molecular profiling of TOPO1: a way to evaluate irinotecan treatment in colorectal cancer? J Clin Oncol. 2016; 34(Suppl): 546.

  • 18

    Shaojun C, Li H, Haixin H, et al. Expression of topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer. Cancer Biol Ther. 2018; 19: 153–159.

  • 19

    Paolicchi E, Vivaldi C, De Gregorio V, et al. Topoisomerase 1 promoter variants and benefit from irinotecan in metastatic colorectal cancer patients. Oncology 2016; 91: 283–288.

  • 20

    Peters GJ, Backus HH, Freemantle S, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002; 1587: 194–205.

  • 21

    Park DJ, Stoehlmacher J, Zhang W, et al. Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. Int J Colorectal Dis. 2002; 17: 46–49.

  • 22

    Leicher LW, Lammertink MH, Offerman SR, et al. Consequences of testing for mismatch repair deficiency of colorectal cancer in clinical practice. Scand J Gastroenterol. 2017; 53: 632–636.

  • 23

    Tarpgaard LS, Qvortrup C, Nygård SB, et al. A phase II study of epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification. BMC Cancer 2016; 16: 91.

  • 24

    Vogel A, Hofheinz RD, Kubicka S, et al. Treatment decisions in metastatic colorectal cancer – beyond first and second line combination therapies. Cancer Treat Rev. 2017; 59: 54–60.

  • 25

    Ozaslan E, Duran AO, Bozkurt O, et al. Analyses of multiple factors for determination of “selected patients” who should receive rechallenge treatment in metastatic colorectal cancer: a retrospective study from Turkey. Asian Pac J Cancer Prev. 2015; 16: 2833–2838.

  • 26

    Chibaudel B, Tournigand C, Bonnetain F, et al. Platinum-sensitivity in metastatic colorectal cancer: towards a definition. Eur J Cancer 2013; 49: 3813–3820.

  • 27

    Suenaga M, Mizunuma N, Matsusaka S, et al. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Des Devel Ther. 2015; 9: 3099–3108.

  • 28

    Bencardino K, Mauri G, Amatu A, et al. Oxaliplatin immune-induced syndrome occurs with cumulative administration and rechallenge: single institution series and systematic review study. Clin Colorectal Cancer 2016; 15: 213–221.

  • 29

    Yanai T, Iwasa S, Hashimoto H, et al. Successful rechallenge for oxaliplatin hypersensitivity reactions in patients with metastatic colorectal cancer. Anticancer Res. 2012; 32: 5521–5526.

  • 30

    Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer – a GERCOR study. J Clin Oncol. 2006; 24: 394–400.

  • 31

    Peixoto RD, Kumar A, Lim HJ, et al. Palliative oxaliplatin-based chemotherapy after exposure to oxaliplatin in the adjuvant setting for colon cancer. J Gastrointest Oncol. 2015; 6: 487–491.

  • 32

    Tonini G, Imperatori M, Vincenzi B, et al. Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. J Exp Clin Cancer Res. 2013; 32: 92.

  • 33

    Ma J, Yang QL, Ling Y. Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer. BMC Cancer 2017; 17: 132.

  • 34

    Santini D, Vincenzi B, Addeo R, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol. 2012; 23: 2313–2318.

  • 35

    Misale S, Yaeger R, Hobor S, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532–536.

  • 36

    Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 2006; 116: 2610–2621.

  • 37

    Simkens LH, van Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015; 385: 1843–1852.

  • 38

    Kamiya M, Yoneyama K, Doi Y, et al. A case of rectal cancer with unresectable liver metastasis responding to rechallenge with FOLFIRI. Gan To Kagaku Ryoho 2016; 43: 2277–2279. [Article in Japanese]

  • 39

    Carter CA, Caroen SZ, Oronsky AL, et al. Dysphonia after bevacizumab rechallenge: a case report. Case Rep Oncol. 2015; 8: 423–425.